Cargando…
COVID-19-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes on SGLT2 inhibitor: a case report
Type 2 diabetes mellitus (DM) patients are at high risk for the development of severe COVID-19. Euglycemic diabetic ketoacidosis (eu-DKA) is a rare life-threatening complication associated with the use of SGLT2 inhibitor that may be unnoticed, particularly in a pandemic setting, due to the absence o...
Autores principales: | Batista, Daniel Valente, Vieira, Carla Antoniana Ferreira de Almeida, Costa, Thomaz Alexandre, Lima, Eduardo Gomes |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592186/ https://www.ncbi.nlm.nih.gov/pubmed/33133998 http://dx.doi.org/10.1007/s13340-020-00473-3 |
Ejemplares similares
-
Euglycemic Diabetic Ketoacidosis With SGLT-2 Inhibitor
por: Manas, F N U, et al.
Publicado: (2021) -
Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors
por: Chow, Erica, et al.
Publicado: (2023) -
Euglycemic Diabetic Ketoacidosis after Discontinuing SGLT2 Inhibitor
por: Alhemeiri, Mohamed, et al.
Publicado: (2022) -
A Case of SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis
por: Rao, Shiavax J, et al.
Publicado: (2022) -
THU387 Euglycemic Diabetic Ketoacidosis And SGLT-2 Inhibitor Use
por: Abrahimi, Nora, et al.
Publicado: (2023)